KZIA News and Press, Kazia Therapeutics Limited From 07/10/24

2024-07-10 10:57:30 ET More on Kazia Financial information for Kazia Read the full article on Seeking Alpha For further details see: Kazia stock soars 142% on study results for brain cancer therapy

A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...

2024-07-10 09:46:33 ET An Australian %Biotech company is already turning heads so far on Wednesday after it was announced results from its GBM-AGILE, which is a hase II/III study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma (NCT03...

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma PR Newswire GBM AGILE trial data shows clinically meaningful improvement in a prespecified secondary analysis for overall survival in paxalisib-treated, newly diagnosed unmethylate...

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER PR Newswire SYDNEY , June 27, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to a...

2024-06-25 06:43:22 ET More on Kazia Financial information for Kazia Read the full article on Seeking Alpha For further details see: Kazia Therapeutics files to sell 1.1M ADSs for holders

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement PR Newswire SYDNEY , May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the ...

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS PR Newswire SYDNEY , May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased t...

2024-04-05 10:30:00 ET April 5, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sector. The newest biotech companies offer therapies for cancer, eye di...

Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases PR Newswire SYDNEY , March 21, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is ...